Tumor Biology

, Volume 35, Issue 10, pp 9693–9699 | Cite as

Association between TNF-α gene 308G>A polymorphism and lung cancer risk: a meta-analysis

  • Haojun Xie
  • Hongmei Yao
  • Yating Huo
  • Ning Li
  • Yuanxiong Cheng
Research Article


Many studies have investigated the association between tumor necrosis factor alpha (TNF-α) gene 308G/A polymorphism and lung cancer risk, but the results were inconsistent. We thus comprehensively searched the PubMed, EMBASE, and BIOSIS Previews databases and extracted data from all eligible articles to estimate the association between TNF-α gene 308G/A polymorphism and lung cancer risk. The pooled odds ratio (OR) with 95 % confidence intervals (CIs) were calculated. Twelve case–control studies in 11 articles involving 2,436 cases and 2,573 controls were included in the meta-analysis to assess the association between TNF-α gene 308G>A polymorphism and susceptibility to lung cancer. Overall, TNF-α gene 308G>A polymorphism was significantly associated with an increased risk of lung cancer for A vs. G (OR = 1.13, 95 % CI 1.00 ~ 1.27, P = 0.04). Subgroup analysis by ethnicity showed that there was a significant association between TNF-α gene 308G>A polymorphism and increased risk of lung cancer in Asians, but not in Caucasians. In subgroup analysis by tumor type, there were significant associations between TNF-α gene 308G>A polymorphism and increased risk of lung cancer in small cell lung cancer (SCLC) for AA+AG vs. GG, in non-small cell lung cancer (NSCLC) for A vs. G, AA vs. GG, and AA+AG vs. GG. No association between the genotypes and different stages of lung cancer was detected. The meta-analysis suggests that TNF-α gene 308G>A polymorphism is associated with an increased risk of lung cancer, particularly among Asians, both for SCLC and NSCLC, considering tumor type.


TNF-α Lung cancer Polymorphism Meta-analysis 


Conflicts of interest



  1. 1.
    Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–80.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.CrossRefPubMedGoogle Scholar
  3. 3.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Ozlu T, Bulbul Y. Smoking and lung cancer. Tuberk Toraks. 2005;53:200–9.PubMedGoogle Scholar
  5. 5.
    Tokuhata GK, Lilienfeld AM. Familial aggregation of lung cancer among hospital patients. Public Health Rep. 1963;78:277–83.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Sellers TA, Bailey-Wilson JE, Elston RC, Wilson AF, Elston GZ, Ooi WL, et al. Evidence for Mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst. 1990;82:1272–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Sellers TA, Chen PL, Potter JD, Bailey-Wilson JE, Rothschild H, Elston RC. Segregation analysis of smoking-associated malignancies: evidence for Mendelian inheritance. Am J Med Genet. 1994;52:308–14.CrossRefPubMedGoogle Scholar
  8. 8.
    Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Matanic D, Beg-Zec Z, Stojanovic D, Matakoric N, Flego V, Milevoj-Ribic F. Cytokines in patients with lung cancer. Scand J Immunol. 2003;57:173–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A. 2001;98:9824–9.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer. 2004;91:1993–5.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003;4:565–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Waters JP, Pober JS, Bradley JR. Tumour necrosis factor and cancer. J Pathol. 2013;230:241–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Yang Y, Luo C, Feng R, Bi S. The TNF-alpha, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2011;137:947–52.CrossRefPubMedGoogle Scholar
  15. 15.
    Shen C, Sun H, Sun D, Xu L, Zhang X, Liu A, et al. Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2011;126:763–70.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang J, Dou C, Song Y, Ji C, Gu S, Xie Y, et al. Polymorphisms of tumor necrosis factor-alpha are associated with increased susceptibility to gastric cancer: a meta-analysis. J Hum Genet. 2008;53:479–89.CrossRefPubMedGoogle Scholar
  17. 17.
    Colakogullari M, Ulukaya E, Oral AY, Aymak F, Basturk B, Ursavas A, et al. The involvement of IL-10, IL-6, IFN-gamma, TNF-alpha and TGF-beta gene polymorphisms among Turkish lung cancer patients. Cell Biochem Funct. 2008;26:283–90.CrossRefPubMedGoogle Scholar
  18. 18.
    Flego V, Badovinac AR, Bulat-Kardum L, Matanic D, Crnic-Martinovic M, Kapovic M, et al. Primary lung cancer and TNF-(alpha) gene polymorphisms: a case-control study in a Croatian population. Med Sci Monit. 2009;15:R361–5.Google Scholar
  19. 19.
    Flego V, Ristic S, Devic Pavlic S, Matanic Lender D, Bulat-Kardum L, Kapovic M, et al. Tumor necrosis factor-alpha gene promoter -308 and -238 polymorphisms in patients with lung cancer as a second primary tumor. Med Sci Monit. 2013;19:846–51.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Helmig S, Aliahmadi N, Schneider J. Tumour necrosis factor-alpha gene polymorphisms in asbestos-induced diseases. Biomarkers. 2010;15:400–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Huang Y. BYLM: TNF-alpha gene polymorphism in patients with lung squamous carcinoma. Natl Med J China. 2005;15:1064–5.Google Scholar
  22. 22.
    Kaabachi S, Kaabachi W, Rafrafi A, Belkis H, Hamzaoui K, Sassi FH. Tumor necrosis factor gene polymorphisms in Tunisian patients with non-small cell lung cancer. Clin Lab. 2013;59:1389–95.PubMedGoogle Scholar
  23. 23.
    Kim JH, Hong YC. No association between tumor necrosis factor-alpha gene polymorphisms and lung cancer risk. Environ Health Toxicol. 2013;28:e2013012.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C, von Wichert P, et al. TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers. 2005;21:157–65.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Shih C, Lee Y. Role of tumour necrosis factor alpha-gene polymorphisms (-238 and -308) in non-small cell lung cancer susceptibility and severity. Lung Cancer-J IASLC. 2005;49:S145.CrossRefGoogle Scholar
  26. 26.
    Stankovic MM, Nestorovic AR, Tomovic AM, Petrovic-Stanojevic ND, Andjelic-Jelic MS, Dopudja-Pantic VB, et al. TNF-(alpha)-308 promotor polymorphism in patients with chronic obstructive pulmonary disease and lung cancer. Neoplasma. 2009;56:348–52.CrossRefPubMedGoogle Scholar
  27. 27.
    Van Dyke AL, Cote ML, Wenzlaff AS, Chen W, Abrams J, Land S, et al. Cytokine and cytokine receptor single-nucleotide polymorphisms predict risk for non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev. 2009;18:1829–40.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Peng WJ, He Q, Yang JX, Wang BX, Lu MM, Wang S, et al. Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk. Mol Biol Rep. 2012;39:5187–94.CrossRefPubMedGoogle Scholar
  29. 29.
    Wang J, Cao C, Luo H, Xiong S, Xu Y, Xiong W. Tumour necrosis factor alpha -308G/A polymorphism and risk of the four most frequent cancers: a meta-analysis. Int J Immunogenet. 2011;38:311–20.CrossRefPubMedGoogle Scholar
  30. 30.
    Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, et al. Non-small-cell lung cancer. Lancet. 2011;378:1727–40.CrossRefPubMedGoogle Scholar
  31. 31.
    Huang G, Cai S, Wang W, Zhang Q, Liu A. Association between XRCC1 and XRCC3 polymorphisms with lung cancer risk: a meta-analysis from case-control studies. PLoS One. 2013;8:e68457.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Huang SX, Wu FX, Luo M, Ma L, Gao KF, Li J, et al. The glutathione S-transferase P1 341C>T polymorphism and cancer risk: a meta-analysis of 28 case-control studies. PLoS One. 2013;8:e56722.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984;312:724–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Tracey KJ, Wei H, Manogue KR, Fong Y, Hesse DG, Nguyen HT, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med. 1988;167:1211–27.CrossRefPubMedGoogle Scholar
  35. 35.
    Wu Y, Antony S, Meitzler JL, Doroshow JH. Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer Lett. 2014;345:164–73.PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34:391–9.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Haojun Xie
    • 1
  • Hongmei Yao
    • 2
  • Yating Huo
    • 1
  • Ning Li
    • 3
  • Yuanxiong Cheng
    • 1
  1. 1.Department of Respiratory and Critical Care Medicine, Nanfang HospitalSouthern Medical UniversityGuangzhouChina
  2. 2.Department of Respiratory MedicineGuizhou Provincial People’s HospitalGuiyangChina
  3. 3.Department of Respiratory and Critical Care MedicineShantou Central HospitalGuangdongChina

Personalised recommendations